M. Carrasquilla-Sotomayor

Economic Costs of Chikungunya Virus in Colombia

OBJECTIVE The aim of the present study was to estimate the economic impact of chikungunya virus (CHIKV) infection in Colombia from a societal perspective. METHODS We conducted a retrospective, bottom-up cost-of-illness study in clinically confirmed cases during the first chikungunya (CHIK) outbreak in Colombia in 2014. Direct and indirect costs were estimated per patient. Economic costs were calculated by the addition of direct costs (direct medical costs and out-of-pocket heath expenditures) and indirect cost as a result of loss of productivity. RESULTS A total of 126 patients (67 children and 59 adults) with CHIK were included. The median of the direct medical cost in children was US

Economic Costs of Bacterial Meningitis: A Systematic Review.

257.9 (interquartile range [IQR] 121.7-563.8), and US

A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia

66.6 (IQR 26.5-317.3) for adults. The productivity loss median expenditures reached US

Hospitalization costs due to severe acute respiratory infection (SARI) in three Central American countries

81.3 (IQR 72.2-203.2) per adult patient. The median economic cost in adults as a result of CHIK was US

Costos economicos de la otitis media aguda. Una revision de la literatura.

152.9 (IQR 101.0-539.6), of which 53.2% was a result of indirect costs. Out-of-pocket expenditures comprised 3.3% of all economic costs. CONCLUSIONS Our study can help health decision makers to properly assess the burden of disease caused by CHIK in Colombia, an endemic tropical country. We recommend to strength the health information systems and to continue investing in public health measures to prevent CHIK.